What Not To Do When FDA Comes Knocking
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA tweaks final guidance on what constitutes interference with FDA inspections to include examples of ‘reasonable’ explanations for sponsor delays; industry had requested many other changes.